AURORA CANNABIS INC (ACB) Fundamental Analysis & Valuation

NASDAQ:ACB • CA05156X8504

3.51 USD
+0.01 (+0.29%)
Last: Mar 6, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ACB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, ACB scores 2 out of 10 in our fundamental rating. ACB was compared to 193 industry peers in the Pharmaceuticals industry. ACB has a bad profitability rating. Also its financial health evaluation is rather negative. ACB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. ACB Profitability Analysis

1.1 Basic Checks

  • ACB had negative earnings in the past year.
  • ACB had a negative operating cash flow in the past year.
  • In the past 5 years ACB reported 4 times negative net income.
  • In the past 5 years ACB reported 4 times negative operating cash flow.
ACB Yearly Net Income VS EBIT VS OCF VS FCFACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1B -2B -3B

1.2 Ratios

  • ACB has a Return On Assets of -11.45%. This is in the better half of the industry: ACB outperforms 66.32% of its industry peers.
  • ACB's Return On Equity of -16.55% is fine compared to the rest of the industry. ACB outperforms 70.47% of its industry peers.
Industry RankSector Rank
ROA -11.45%
ROE -16.55%
ROIC N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ACB Yearly ROA, ROE, ROICACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200 -250

1.3 Margins

  • ACB's Gross Margin of 1.35% is in line compared to the rest of the industry. ACB outperforms 50.78% of its industry peers.
  • ACB's Gross Margin has declined in the last couple of years.
  • ACB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
ACB Yearly Profit, Operating, Gross MarginsACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ACB Health Analysis

2.1 Basic Checks

  • ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ACB has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ACB has less shares outstanding
  • Compared to 1 year ago, ACB has an improved debt to assets ratio.
ACB Yearly Shares OutstandingACB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
ACB Yearly Total Debt VS Total AssetsACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.2 Solvency

  • Based on the Altman-Z score of -10.46, we must say that ACB is in the distress zone and has some risk of bankruptcy.
  • ACB's Altman-Z score of -10.46 is on the low side compared to the rest of the industry. ACB is outperformed by 70.98% of its industry peers.
  • ACB has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ACB (0.06) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -10.46
ROIC/WACCN/A
WACC8.76%
ACB Yearly LT Debt VS Equity VS FCFACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

2.3 Liquidity

  • A Current Ratio of 3.06 indicates that ACB has no problem at all paying its short term obligations.
  • The Current ratio of ACB (3.06) is comparable to the rest of the industry.
  • A Quick Ratio of 1.48 indicates that ACB should not have too much problems paying its short term obligations.
  • ACB's Quick ratio of 1.48 is on the low side compared to the rest of the industry. ACB is outperformed by 62.18% of its industry peers.
Industry RankSector Rank
Current Ratio 3.06
Quick Ratio 1.48
ACB Yearly Current Assets VS Current LiabilitesACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ACB Growth Analysis

3.1 Past

  • The earnings per share for ACB have decreased strongly by -502.65% in the last year.
  • Looking at the last year, ACB shows a quite strong growth in Revenue. The Revenue has grown by 16.54% in the last year.
  • The Revenue has been growing slightly by 6.94% on average over the past years.
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
Revenue 1Y (TTM)16.54%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%

3.2 Future

  • The Earnings Per Share is expected to grow by 103.58% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 1.81% on average over the next years.
EPS Next Y-1574.6%
EPS Next 2Y162.07%
EPS Next 3Y55.18%
EPS Next 5Y103.58%
Revenue Next Year6.2%
Revenue Next 2Y1.66%
Revenue Next 3Y5.54%
Revenue Next 5Y1.81%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ACB Yearly Revenue VS EstimatesACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ACB Yearly EPS VS EstimatesACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

2

4. ACB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 13.93, the valuation of ACB can be described as correct.
  • ACB's Price/Forward Earnings ratio is rather cheap when compared to the industry. ACB is cheaper than 84.46% of the companies in the same industry.
  • ACB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.57, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 13.93
ACB Price Earnings VS Forward Price EarningsACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACB Per share dataACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ACB's earnings are expected to grow with 55.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y162.07%
EPS Next 3Y55.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACB Dividend Analysis

5.1 Amount

  • No dividends for ACB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACB Fundamentals: All Metrics, Ratios and Statistics

AURORA CANNABIS INC

NASDAQ:ACB (3/6/2026, 8:00:00 PM)

3.51

+0.01 (+0.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)06-16
Inst Owners13.02%
Inst Owner Change-24.89%
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap199.05M
Revenue(TTM)373.12M
Net Income(TTM)-88.74M
Analysts74
Price Target5.2 (48.15%)
Short Float %14.48%
Short Ratio5.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-336.98%
Min EPS beat(2)-587.94%
Max EPS beat(2)-86.02%
EPS beat(4)0
Avg EPS beat(4)-329.23%
Min EPS beat(4)-587.94%
Max EPS beat(4)-86.02%
EPS beat(8)2
Avg EPS beat(8)402.7%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.71%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.46%
Revenue beat(4)3
Avg Revenue beat(4)0.88%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)2.46%
Revenue beat(8)6
Avg Revenue beat(8)4.2%
Revenue beat(12)9
Avg Revenue beat(12)4.15%
Revenue beat(16)9
Avg Revenue beat(16)1.91%
PT rev (1m)-9.18%
PT rev (3m)-9.86%
EPS NQ rev (1m)-250.01%
EPS NQ rev (3m)-250.01%
EPS NY rev (1m)0%
EPS NY rev (3m)-682.17%
Revenue NQ rev (1m)-18.09%
Revenue NQ rev (3m)-18.09%
Revenue NY rev (1m)-4.41%
Revenue NY rev (3m)-2.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 13.93
P/S 0.73
P/FCF N/A
P/OCF N/A
P/B 0.51
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)0.25
Fwd EY7.18%
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS4.83
BVpS6.94
TBVpS6.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.45%
ROE -16.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.35%
FCFM N/A
ROA(3y)-55.32%
ROA(5y)-62.11%
ROE(3y)-90.28%
ROE(5y)-91.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-29.39%
F-Score3
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.54%
Cap/Sales 5.81%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.06
Quick Ratio 1.48
Altman-Z -10.46
F-Score3
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)56.47%
Cap/Depr(5y)106.5%
Cap/Sales(3y)8.76%
Cap/Sales(5y)35.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-502.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-94.83%
EPS Next Y-1574.6%
EPS Next 2Y162.07%
EPS Next 3Y55.18%
EPS Next 5Y103.58%
Revenue 1Y (TTM)16.54%
Revenue growth 3Y11.86%
Revenue growth 5Y6.94%
Sales Q2Q%6.79%
Revenue Next Year6.2%
Revenue Next 2Y1.66%
Revenue Next 3Y5.54%
Revenue Next 5Y1.81%
EBIT growth 1Y-17.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year111.29%
EBIT Next 3Y38.33%
EBIT Next 5Y21.79%
FCF growth 1Y63.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.56%
OCF growth 3YN/A
OCF growth 5YN/A

AURORA CANNABIS INC / ACB FAQ

Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?

ChartMill assigns a fundamental rating of 2 / 10 to ACB.


What is the valuation status of AURORA CANNABIS INC (ACB) stock?

ChartMill assigns a valuation rating of 2 / 10 to AURORA CANNABIS INC (ACB). This can be considered as Overvalued.


What is the profitability of ACB stock?

AURORA CANNABIS INC (ACB) has a profitability rating of 1 / 10.